Stockscreener 앱 받기
17.31
1.84%
0.559
전일 마감가:
$16.75
열려 있는:
$16.86
하루 거래량:
215.85K
Relative Volume:
0.17
시가총액:
$1.43B
수익:
$46.02M
순이익/손실:
$-70.80M
주가수익비율:
-9.511
EPS:
-1.82
순현금흐름:
$-1.61M
1주 성능:
+15.03%
1개월 성능:
+54.87%
6개월 성능:
+106.77%
1년 성능:
+109.06%
1일 변동 폭
$16.59
$17.30
1주일 범위
$13.61
$17.25
52주 변동 폭
$3.91
$17.25
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
명칭
Eyepoint Pharmaceuticals Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
EYPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
17.30 | 1.38B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.89 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
728.93 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.69 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
904.77 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.60 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Pharmaceuticals Inc 주식(EYPT)의 최신 뉴스
How EyePoint Pharmaceuticals Inc. (PV3B) stock responds to job market shiftsMarket Growth Review & Community Consensus Trade Signals - Newser
Can EyePoint Pharmaceuticals Inc. (PV3B) stock deliver strong annual returnsWeekly Trading Summary & Real-Time Volume Trigger Notifications - Newser
How buyback programs support EyePoint Pharmaceuticals Inc. (PV3B) stockMarket Risk Report & Smart Investment Allocation Tips - Newser
Will EyePoint Pharmaceuticals Inc. stock outperform value stocksQuarterly Portfolio Review & AI Powered Trade Plan Recommendations - Newser
Eyepoint Pharmaceuticals stock hits 52-week high at 15.0 USD - Investing.com
Eyepoint Pharmaceuticals stock hits 52-week high at 15.0 USD By Investing.com - Investing.com Nigeria
Will EyePoint Pharmaceuticals Inc. (PV3B) stock outperform energy sector in 2025CPI Data & Weekly Return Optimization Plans - Newser
Is EyePoint Pharmaceuticals Inc. (PV3B) stock positioned for secular growthWeekly Earnings Recap & Fast Entry Momentum Alerts - Newser
EyePoint Pharmaceuticals: Promising Outlook for Duravyu in Wet AMD Treatment and Strategic Growth Potential - TipRanks
EyePoint Pharmaceuticals Director Sells Shares - TradingView
XTX Topco Ltd Acquires 94,210 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
What drives EyePoint Pharmaceuticals Inc stock priceEvening Star Patterns & Exceptional Return Capital - earlytimes.in
Investors Appear Satisfied With EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Prospects As Shares Rocket 26% - 富途牛牛
EyePoint Pharmaceuticals (EYPT) Is Up 8.4% After Positive Phase 3 Safety Review for DURAVYU - Sahm
Officer/Dir Lurker Files To Sell 500 Of EyePoint Pharmaceuticals Inc [EYPT] - TradingView
What analysts say about EyePoint Pharmaceuticals Inc PV3B stockHigh Dividend Yield Stocks & Access Free Risk Analysis Before You Invest - earlytimes.in
Avoiding Lag: Real-Time Signals in (EYPT) Movement - news.stocktradersdaily.com
EyePoint Pharmaceuticals (EYPT): A Fresh Valuation Look Following Key DURAVYU Phase 3 Safety Review Completion - Sahm
Will EyePoint Pharmaceuticals Inc. stock see PE expansionJuly 2025 Patterns & Stepwise Entry and Exit Trade Signals - BỘ NỘI VỤ
Eyepoint Pharmaceuticals stock hits 52-week high at $14.94 By Investing.com - Investing.com Nigeria
Eyepoint Pharmaceuticals stock hits 52-week high at $14.94 - Investing.com
EyePoint receives second consecutive positive recommendation from DSMC - Modern Retina
Why Institutions Believe Infibeam Avenues Limited Is Undervalued TodayStock Watchlist Updates & Collaborate and Win Together - earlytimes.in
EyePoint Pharmaceuticals (EYPT) Clears Phase 3 Safety Hurdle for DURAVYU—Is a New Wet AMD Era Ahead? - Sahm
Can EyePoint Pharmaceuticals Inc. (PV3B) stock sustain double digit ROETrade Risk Report & Detailed Earnings Play Alerts - newser.com
EyePoint Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals stock maintains Buy rating at H.C. Wainwright - Investing.com
Will EyePoint Pharmaceuticals Inc. (PV3B) stock beat growth indexesExit Point & Daily Technical Forecast Reports - newser.com
Is EyePoint Pharmaceuticals Inc. (PV3B) stock trading at attractive multiplesEarnings Risk Summary & Smart Swing Trading Alerts - newser.com
Is EyePoint Pharmaceuticals Inc. stock attractive for passive investorsJuly 2025 Summary & Scalable Portfolio Growth Methods - newser.com
Why ETFs are accumulating EyePoint Pharmaceuticals Inc. (PV3B) stock2025 Biggest Moves & Free Reliable Trade Execution Plans - newser.com
What margin trends mean for EyePoint Pharmaceuticals Inc. stockForecast Cut & Daily Technical Forecast Reports - newser.com
Will EyePoint Pharmaceuticals Inc. (PV3B) stock hit Wall Street targetsQuarterly Earnings Summary & Daily Oversold Bounce Ideas - newser.com
EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review - Yahoo Finance
How EyePoint Pharmaceuticals Inc. stock performs in high volatility marketsGold Moves & Precise Entry and Exit Recommendations - newser.com
Is EyePoint Pharmaceuticals Inc. stock ready for breakout2025 Bull vs Bear & Real-Time Volume Analysis - newser.com
Eyepoint Pharmaceuticals Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.67%
자본화:
|
볼륨(24시간):